Citizen Science Magazine; everyone's a scientist “RIVM is committed to being innovative, and becoming a key player in citizen science is fully in line with that goal,” says Danielle Timmermans, Chief Science Officer for Risk Communication at RIVM
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Teen vaccination against meningococcal disease starts From mid-September, young people born between 1 May and 31 December 2004 will receive an invitation for a vaccination against meningococcal disease.
Health and Well-being through Effective Blue-Green Space Design and Governance During World Water Week (August 26 – 31, 2018), the Dutch National Institute for Public Health and the Environment, RIVM, is facilitating a session on Health and Well-being through effective Blue-G
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
Protection of Defence personnel against health risks of chromium-6 was inadequate From 1984-2006, employees of the Dutch Ministry of Defence were exposed to chromium-6 during maintenance work.
First products Dutch Public Health Foresight study available in English In 2017, RIVM launched a Trend Scenario, as well as three thematic reports about the future demand for health care, technology and wider determinants of health.
New standard for exposure assessment of cleaning products RIVM has updated the standard for exposure assessment of cleaning products in the ConsExpo Cleaning Products Fact Sheet.
Trend scenario PHF- 2018 identifies societal challenges for the future If historical trends continue unchanged, dementia will be the leading cause of disease burden in 2040 and the main cause of death.
Meningococcal immunisation recommendations re-examined Meningococcal disease is a very serious infectious disease that can cause meningitis or blood poisoning. Children are immunised against meningococcal serogroup C at 14 months.